BFA
GALT icon

BlackRock Fund Advisors’s Galectin Therapeutics GALT Stock Holding History

BlackRock Fund Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$80K Buy
81,235
+2,356
+3% +$2.09K ﹤0.01% 3661
2016
Q3 		$89K Sell
78,879
-76
-0.1% -$135 ﹤0.01% 3645
2016
Q2 		$116K Buy
78,955
+19,967
+34% +$29.3K ﹤0.01% 3629
2016
Q1 		$84K Sell
58,988
-4,182
-7% -$5.62K ﹤0.01% 3702
2015
Q4 		$104K Buy
63,170
+3,506
+6% +$8.03K ﹤0.01% 3720
2015
Q3 		$140K Sell
59,664
-1,578
-3% -$3.72K ﹤0.01% 3611
2015
Q2 		$167K Sell
61,242
-460,962
-88% -$1.39M ﹤0.01% 3590
2015
Q1 		$1.75M Buy
522,204
+17,182
+3% +$61.4K ﹤0.01% 3157
2014
Q4 		$1.75M Buy
505,022
+70,024
+16% +$309K ﹤0.01% 3174
2014
Q3 		$2.19M Sell
434,998
-18,414
-4% -$143K ﹤0.01% 3113
2014
Q2 		$6.26M Buy
453,412
+392,211
+641% +$4.88M ﹤0.01% 2704
2014
Q1 		$937K Buy
61,201
+14,861
+32% +$212K ﹤0.01% 3197
2013
Q4 		$374K Buy
46,340
+1,940
+4% +$17.9K ﹤0.01% 3267
2013
Q3 		$443K Buy
44,400
+4,239
+11% +$28.6K ﹤0.01% 3212
2013
Q2 		$171K Buy
+40,161
New +$164K ﹤0.01% 3376

Other funds holding GALT

DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

BlackRock Fund Advisors's GALT Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Galectin Therapeutics (GALT) stake by 3% in Q4 2016, buying an estimated $2.09K and bringing the position to 81,235 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #3661.

BlackRock Fund Advisors first reported a position in GALT in Q2 2013 and has held it in 15 quarters since. The position peaked at $6.26M in Q2 2014. 43 funds tracked by Wall St. Rank hold GALT as of Q4 2016.

  • BlackRock Fund Advisors held 81,235 shares of Galectin Therapeutics worth $80K as of Q4 2016.
  • BlackRock Fund Advisors bought 2,356 Galectin Therapeutics shares in Q4 2016, an estimated $2.09K.
  • Galectin Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3661 holding.
  • BlackRock Fund Advisors first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Galectin Therapeutics position peaked at $6.26M in Q2 2014.
  • 43 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.